【摘要】 目的:比较利培酮、氯丙嗪对首发精神分 裂症病人维持治疗的疗效和安全性。方法:对经利 培酮或氯丙嗪治疗后疗效达临床痊愈或显进而出院 的120例首发精神分裂症病人随访2a,每3mo评 定BPRS和TESS,采用BPRS的核心条目(4,7,11, 12和15)判定是否复发,用TESS评定不良反应。 结果:利培酮组复发率1a为5%,2a为23%;氯 丙嗪组复发率1a为17%,2a为32%,1a复发率 利培酮组明显低于氯丙嗪组(χ2=4.23,P= 0.040)。利培酮组除女病人出现月经紊乱外,抗胆 碱能反应、嗜睡、头晕、皮肤症状等明显低于氯丙嗪 组。结论:利培酮和氯丙嗪对首发精神分裂症病人 的维持治疗均有良好效果,而利培酮不良反应少,耐 受性好,更适于维持治疗。更多还原

【Abstract】 AIM: To compare the safety and efficacy of risperidone, chlorpromazine in the maintenance treatment in first-episode schizophrenia. METHODS: A two-year follow-up study was carried out in 120 discharged schizophrenia who were much improved by risperidone or chlorpromazine treatment. During this period, the Brief Psychiatric Rating Scales (BPRS) and Treatment Emergent Symptoms Scale (TESS) were used to evaluat once every three months, and the major items of BPRS (4,7,11,12 and 15 items) were used to assess whether the patients had relapsed or not. TESS were used to assess adverse reactions. RESULTS: At the end of the first year, 5 % of patients in the risperidone group and 17 % of patients in the chlorpromazine group had relapsed. At the end of the second years, 23 % of patients in the risperidone group and 32 % of patients in the chlorpromazine group had relapsed, namely the relapse rates of the first year in the risperidone group was significantly lower than in the chlorpromazine group.The adverse reactions of anticholinergic actions, dizziness, somnolence, and skin lesions, etc in the risperidone group were significantly fewer than in the chlorpromazine group. CONCLUSION: Both risperidone and chlorpromazine are efficacious in the maintenance treatment of the first-episode schizophrenia, and adverse reactions is fewer, it is more safe to use risperidone.更多还原